Matrix Bio - Long-lived Species Inspired Longevity Biotech

VITARAT

Cancer

Naked mole rats (NMR) are long-lived rodents with a lifespan of up to 40 years, compared to normal rats which live about three years. Unlike other rodents, NMR are found to be cancer resistant. Previous research by the Gorbunova lab has demonstrated cancer resistance in NMR is modulated by the abundance of high molecular weight hyaluronic acid (HMW-HA) in tissues. Additional research has demonstrated that transgenic mice expressing naked mole rat hyaluronan synthase gene (NHAS2) have fewer tumours, improved health, and live 10% longer than mice without the transgene. Matrix Bio, in this project funded by VitaDAO, aims to increase HA in human patients and translate these findings into the clinic, this project will screen and develop small molecule inhibitors of hyaluronidases, the enzymes that break down hyaluronic acid. These compounds can be used for cancer treatment and are expected to increase human healthspan and lifespan.

Description

Matrix Bio, in this project funded by VitaDAO, aims to increase HA in human patients and translate these findings into the clinic, this project will screen and develop small molecule inhibitors of hyaluronidases, the enzymes that break down hyaluronic acid. These compounds can be used for cancer treatment and are expected to increase human healthspan and lifespan.

Team

0x00763…44da7

Owner

Organisation

University of Rochester

Experiment Cost

$300,000.00

Project Score

Technology Readiness Level

PRE-TRL

TRL 1

TRL 2

Project Progress

All updates

All categories

Timeline

Matrix Bio - Long-lived Species Inspired Longevity Biotech

VITARAT

Cancer

Description

Team

0x00763…44da7

Owner

Organisation

University of Rochester

Experiment Cost

$300,000.00

Project Score

Technology Readiness Level

PRE-TRL

TRL 1

TRL 2

Project Progress

All updates

All categories

Timeline

Rationale

The project has conducted in vivo experiments in NMR-HAS2 transgenic mice — a disease-relevant model — demonstrating measurable efficacy outcomes including reduced tumor burden, improved healthspan markers, and ~10% lifespan extension (Zhang et al. 2022 preprint). These results constitute early proof-of-concept in a disease-relevant in vivo system with quantitative outcomes, meeting TRL 3 criteria. However, confidence is medium rather than high because the in vivo efficacy was demonstrated via genetic overexpression (transgenic model) rather than pharmacological intervention with the actual drug candidate; the planned pharmacological in vivo validation (Program 2) has not yet been conducted, and translatability concerns exist regarding NMR-specific HAS2 biology.

Assessment

High Confidence

RecommendationSUPPLEMENT

Total Score3.20

Overall Assessment

Matrix Bio scores a final weighted score of 3.20 out of 5.00, placing it in the moderate range for a TRL 3 project. The project's greatest strengths lie in its therapeutic relevance (strong published evidence from transgenic mouse models, well-characterized CD44-mediated mechanism), the caliber of the scientific team (world-leading PI with deep domain expertise), therapeutic optionality across multiple indications, and a large addressable market. However, the project is held back by its very early discovery stage—no optimized lead candidates exist, the HTS campaign has not yet begun, and no efficacy data in disease models has been generated. The IP position is promising but aspirational, with no patents filed. Critical translational risks remain, particularly whether hyaluronidase inhibition can produce sufficient vHMW-HA in human tissues given species-specific HAS2 differences. The absence of a detailed R&D plan, defined milestones, and timeline is a notable gap. Overall, this is a high-risk, high-reward early-stage program with strong scientific foundations but significant uncertainty in feasibility and translatability. The project would benefit most from completing the planned HTS campaign, generating in vivo efficacy data in cancer models, and addressing the vHMW-HA translatability question before further investment decisions.

Weighted Score

Therapeutic Relevance

The mechanism of action—increasing HMW-HA via hyaluronidase inhibition—has clear therapeutic relevance supported by strong published evidence. Transgenic mice expressing NMR HAS2 showed reduced tumors, improved healthspan, and ~10% lifespan extension (Zhang et al. 2022). The CD44-mediated signaling pathway for tumor suppression is well-characterized. However, a key concern is that vHMW-HA cytoprotective effects may require NMR-specific HAS2 amino acid variations absent in humans, introducing translational uncertainty. The mixed literature on hyaluronan's role in metastasis and the controversy around HMW-HA in cancer progression prevent a top score.

Therapeutic Optionality

Beyond the primary cancer prevention/treatment indication, the project identifies multiple secondary applications including wound healing, arthritis, joint conditions, skin-related conditions, and broader healthspan/longevity indications. The ECM-modulating mechanism provides a plausible biological basis for these diverse applications. However, these remain speculative with no supporting data for non-cancer indications, and the systemic efficacy in humans is unproven.

Intellectual Property

The IP strategy has promising elements: a proprietary functional screening assay, one undisclosed prioritized target (kept confidential for IP protection), an existing natural product hit with potential for formulation/modification patents, and a plan to generate patentable NCEs through HTS and medicinal chemistry. Senior reviewers scored IP potential at 3.7/5. However, no patents have been filed yet, no freedom-to-operate assessment is disclosed, patent application status fields are blank, and the IP strategy is still largely aspirational. The composition-of-matter IP will depend on successful HTS and med chem campaigns that haven't started.

Utility Of Candidates

An existing tool compound with EC50 ~20 µM has been identified from a ~3k compound screen and shows in vivo activity in increasing HA levels in mouse and human tissues, demonstrating target druggability. However, this is a single early hit with modest potency (20 µM), no optimized lead candidates exist, no efficacy data in disease models has been generated yet (planned but not executed), and the HTS campaign and medicinal chemistry optimization are still in planning stages. The project is at the very early discovery phase with no lead compounds selected or optimized.

Prospects For Safety

The biological rationale suggests a favorable safety profile—HMW-HA is a naturally occurring molecule and the transgenic mouse model showed improved health without reported toxicity. However, no formal safety or toxicity studies have been conducted. Key safety concerns include: potential interference with chemotherapy and immunotherapy efficacy if used in combination, the mixed literature on hyaluronan's dual role in cancer (HMW-HA linked to cancer resistance but also potentially involved in malignant progression), and unknown systemic effects of hyaluronidase inhibition in humans. Safety assessment is essentially theoretical at this stage.

Prospects For Gmp Cmc

As a small-molecule program, the general manufacturing pathway is well-established, which is favorable. However, no lead compound has been selected, so CMC considerations are entirely premature. The existing hit is a natural product (which can present sourcing and synthesis challenges), and no manufacturing feasibility, scalability, or formulation work has been discussed. The project is too early to meaningfully assess GMP/CMC prospects.

Prospects For Clinical Development

Clinical development prospects are distant and poorly defined. No detailed R&D plan, milestones, or timeline has been provided. The project is at early discovery stage with HTS and med chem campaigns not yet initiated. Key translational risks remain unaddressed—particularly whether hyaluronidase inhibition can systemically increase HMW-HA in humans and whether this translates to clinical benefit. The regulatory pathway for a cancer prevention indication would be particularly challenging. Senior reviewers noted 'no detailed plans presented' and rated feasibility/data at only 3.5/5.

Commercial Potential

The addressable market is enormous—19.3 million new cancer cases and 10 million deaths annually worldwide. The mechanism is unique with little direct competition, providing potential market differentiation. Senior reviewers scored market advantage at 3.5/5. Multiple potential indications (cancer, longevity, skin/joint conditions) expand commercial opportunity. However, the cancer prevention market is notoriously difficult to commercialize, the project is very early stage with high attrition risk, and the competitive landscape for cancer therapeutics broadly is intense.

Organization And Team Fit

The team is led by Vera Gorbunova, a world-leading expert in comparative biology of aging and the originator of the NMR HMW-HA research, with an endowed professorship and numerous prestigious awards. Senior reviewers scored the science team at 4.6/5. VitaDAO provides biotech/DeSci company formation support and scientific/business evaluation expertise. However, the team composition beyond the PI is not well-defined for the newco, potential gaps in drug development expertise (medicinal chemistry, regulatory, clinical) are not addressed, and the organizational structure of Matrix Bio is still being formed.